Tatva Chintan Pharma Chem Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/spbxrsc6ceof130idqadxg6l.pdf

Key Takeaways


Financial Performance & Cost Environment

Pillai: "Not actually because the prices are going up due to the geopolitical situation and other things. But gradually, it is being absorbed by our customers. Our customers are cooperating, although they are not being absorbed at 100% level, but probably we believe that it will gradually be absorbed. And we don't intend to change anything on our guidance in that matter."

Electrolyte Salts: The New Growth Engine


SDA: Steady Demand, Euro 7 Catalyst Ahead

Chintan Shah: "customers also know that there are only two suppliers for this product. So, they always try to keep a balance. Maybe if I say I get most of the share, then I mean I may be getting 70% of the volume. You will never get more from any particular customer for any particular product because that is how they want to keep both of us engaged in this business."

PASC & Agro Intermediates: Near-Term Drag, Structural Promise

Chintan Shah: "this is being done by a new technology, which has been fully developed in-house. And we have not seen any single patent or process filed by this route of chemistry. So it is something exceptional that our team has achieved, and we are really proud of that."

New Verticals: Pharma & Semiconductor

Chintan Shah: "if SDA, I have been saying all these years is a very difficult entry barrier, most difficult part to get an entry into this. You wait for the opportunity for years. This particular segment is even worse than that. Demands a lot of patience."

Capacity & Capex: Dahej Now, Jolva Next


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growth~25% (range: 20–25%, staying conservative due to geopolitical uncertainties)FY27
EBITDA margin20% to 22% on a realistic basisFY27
Electrolyte Salts revenue contribution8% to 10% of overall revenueFY27
SDA revenueAt least 20% growth, reaching ₹250–300 CrFY27
Pharma revenue₹70–75 Cr, completely new add-onFY27
Jolva groundbreakingBreak ground within 60 days (mid-July)Q1 FY27
Jolva commercial productionProduction start, 18–20 months from planning stageJan–Mar 2028
Semiconductor first dispatchFirst commercial-scale batch dispatchedQ1 FY27
Semiconductor final commercializationScale-up gradualEnd of 2028 to early 2029
Hybrid battery commercial startGo onlineNov–Dec 2026
Hybrid battery full scaleRamp-up to full scale when vehicle launches mid-2028Late 2027 to early 2028
Dahej full potentialReach ₹850–900 Cr revenue capacityFY28

Key Metrics

MetricQ4 FY26
Operating revenue₹134.1 cr, +24% YoY and +2% QoQ
EBITDA₹28.1 cr, +214% YoY and +10% QoQ
EBITDA margin21.0%, supported by better product mix and improved operating leverage
Phase Transfer Catalyst revenue₹31.1 cr, -20% YoY and +11% QoQ
Electrolyte Salts revenue₹13.1 cr, +1,378% YoY and +865% QoQ
Pharma and Agro Intermediates and Specialty Chemicals revenue₹35.8 cr, +10% YoY and -24% QoQ; sequential decline due to production ramp-up challenges at new facility
Structure Directing Agents revenue₹52.5 cr, +52% YoY and -2% QoQ
Full-year FY26 revenueIn excess of ₹500 cr, milestone year marking 30 years of operations
Revenue growth guidance for FY27~25%
EBITDA margin guidance for FY2720% to 22%
Electrolyte Salts expected revenue contribution in FY278% to 10% of total revenue
SDA revenue guidance for FY27₹250 cr to ₹300 cr, at least 20% growth
Pharma revenue expectation for FY27₹70 cr to ₹75 cr, completely new add-on from three products commercializing
Current capacity utilization80% to 85%
Current facility peak revenue potential₹850 cr to ₹900 cr, with minor debottlenecking capex of ₹10 cr to ₹12 cr per year
Jolva greenfield Phase 1 revenue potential₹400 cr to ₹500 cr; groundbreaking in Q1 FY27, commercial production early 2028
Jolva project total capex₹250 cr to ₹270 cr, with ₹100 cr in FY27 and ₹175 cr in FY28
Effective tax rate~26% annual; Q4 at 38% due to carryforward losses and deferred tax on heavy capex
Semiconductor chemicals impurity levels achievedBelow 1 part per billion, in the 1,000 parts per trillion range